Showing results (1-10 of 146) with videos related to
Sort By:
Pageof 15
Giornale Italiano Di Nefrologia : Organo Ufficiale Della Societa Italiana Di Nefrologia|August 27, 2002
[Hyperaldosteronism and simultaneous pheocromocytoma: a puzzle case]F Mallamaci, G Tripepi, G CaridiNephrology, Dialysis, Transplantation : Official Publication of the European Dialysis and Transplant Association - European Renal Association|October 29, 2000
AGEs and carbonyl stress: potential pathogenetic factors of long-term uraemic complicationsC Zoccali, F Mallamaci, G TripepiJournal of Nephrology|October 26, 2005
Leptin in end stage renal disease (ESRD): a link between fat mass, bone and the cardiovascular systemF Mallamaci, G Tripepi, C ZoccaliNephrology, Dialysis, Transplantation : Official Publication of the European Dialysis and Transplant Association - European Renal Association|March 1, 1997
The heart rate response pattern to dialysis hypotension in haemodialysis patientsC Zoccali, G Tripepi, F Mallamaci, et al.Nephrology, Dialysis, Transplantation : Official Publication of the European Dialysis and Transplant Association - European Renal Association|February 24, 2001
Autonomic neuropathy is linked to nocturnal hypoxaemia and to concentric hypertrophy and remodelling in dialysis patientsC Zoccali, F Mallamaci, G Tripepi, et al.Kidney International|June 16, 2006
Low triiodothyronine and survival in end-stage renal diseaseC Zoccali, F Mallamaci, G Tripepi, et al.Kidney International|December 9, 1998
Plasma adrenomedullin during acute changes in intravascular volume in hemodialysis patientsF Mallamaci, C Zoccali, S Parlongo, et al.Kidney International|March 2, 2006
Urotensin II is an inverse predictor of incident cardiovascular events in end-stage renal diseaseC Zoccali, F Mallamaci, G Tripepi, et al.Kidney International|October 19, 2007
Urotensin II is an inverse predictor of death and fatal cardiovascular events in chronic kidney diseaseP Ravani, G Tripepi, P Pecchini, et al.Nutrition, Metabolism, and Cardiovascular Diseases : NMCD|December 27, 2016
Active vitamin D treatment in CKD patients raises serum sclerostin and this effect is modified by circulating pentosidine levelsC Torino, P Pizzini, S Cutrupi, et al.Pageof 15